Avid Radiopharmaceuticals, Inc. Release: FDA Advisory Committee Provides Clear Path Forward For Development of Amyloid Imaging Agents For Alzheimer’s Disease

SILVER SPRING, Md.--(BUSINESS WIRE)--Avid Radiopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) Peripheral and CNS Advisory Committee provided strong support for development of amyloid imaging agents to test for the presence or absence of Alzheimer’s disease pathology in people with symptoms of cognitive impairment. Avid’s Phase II amyloid imaging compound, 18F-AV-45 (AV-45) is well positioned to rapidly enter late stage development based on the FDA Advisory Committee recommendations.